Description: Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.
Home Page: microbix.com
265 Watline Avenue
Mississauga,
ON
L4Z 1P3
Canada
Phone:
905 361 8910
Officers
Name | Title |
---|---|
Mr. Cameron L. Groome | Pres, CEO & Director |
Mr. James S. Currie | Chief Financial Officer |
Dr. Kenneth Hughes Ph.D. | Chief Operating Officer |
Dr. Mark Luscher Ph.D. | Sr. VP of Scientific Affairs |
Mr. Philip Casselli | Sr. VP of Sales, Bus. Devel. & Marketing |
Mr. Christopher B. Lobb | Compliance Officer, Gen. Counsel & Sec. |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 9.8232 |
---|---|
Trailing PE: | 29.55 |
Price-to-Book MRQ: | 2.4825 |
Price-to-Sales TTM: | 2.137 |
IPO Date: | |
Fiscal Year End: | September |
Full Time Employees: | 0 |